<code id='87C5E7987B'></code><style id='87C5E7987B'></style>
    • <acronym id='87C5E7987B'></acronym>
      <center id='87C5E7987B'><center id='87C5E7987B'><tfoot id='87C5E7987B'></tfoot></center><abbr id='87C5E7987B'><dir id='87C5E7987B'><tfoot id='87C5E7987B'></tfoot><noframes id='87C5E7987B'>

    • <optgroup id='87C5E7987B'><strike id='87C5E7987B'><sup id='87C5E7987B'></sup></strike><code id='87C5E7987B'></code></optgroup>
        1. <b id='87C5E7987B'><label id='87C5E7987B'><select id='87C5E7987B'><dt id='87C5E7987B'><span id='87C5E7987B'></span></dt></select></label></b><u id='87C5E7987B'></u>
          <i id='87C5E7987B'><strike id='87C5E7987B'><tt id='87C5E7987B'><pre id='87C5E7987B'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:fashion    - browse:315
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge